Real-world treatment planning for stage II–III HR+ HER2+ breast cancer
Part of Cancer, Skin clinical trials.
This trial looks at how well a standard “neoadjuvant” treatment plan works in real-world patients. It is for people newly diagnosed with stage II–III HR+ breast cancer and aims to see whether treatment gives expected outcomes in everyday care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have HR+/HER2+ early breast cancer (not HR+/HER2- or other types)
- Have stage II or stage III breast cancer and be entering treatment for the first time
- Plan to start a standard chemotherapy-based “neoadjuvant” regimen chosen by the study doctor (examples include TCbHP, THP, EC-THP, or AC-THP)
- Have a good overall function score (Karnofsky Performance Status 70 or higher)
- You should not have had any cancer treatment before (no chemotherapy, radiation, targeted therapy, or hormone/endocrine therapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests whether switching between two targeted therapy combinations can help women with HER2-positive advanced breast cancer that has progressed after previous treatments. It aims to find a new effective option for people who have already tried one or two lines of therapy.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
This trial tests whether adding a targeted therapy (a CDK4/6 inhibitor) to standard hormone therapy can let some people safely skip chemotherapy. It is for early-stage, hormone-positive breast cancer that is also HER2-positive, and aims to reduce side effects while keeping the cancer from coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.